Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cell protection through PPAR nuclear receptor activation].

Dominique Deplanque1

  • 1EA 1046, Laboratoire de Pharmacologie, Faculté de Médecine, Lille, France. d-deplanque@chru-lille.fr

Therapie
|June 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

Combination of Clopidogrel With PPIs or P-CABs: Beware of Risky Interactions.

Stroke·2026
Same author

Comparison of the effect of donepezil and a combination of donepezil and mefloquine (THN201) on cognition during a scopolamine challenge in healthy participants.

Experimental and clinical psychopharmacology·2026
Same author

Being 80 years old in a rapidly changing world….

Therapie·2026
Same author

Accelerating recruitment in clinical trials: A strategic challenge.

Therapie·2026
Same author

Therapie·2026
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Peroxisome proliferator-activated receptors (PPARs) show promise in cellular protection against ischemia and neurodegenerative diseases. Further research into selective PPAR agonists could offer new therapeutic strategies.

Area of Science:

  • Molecular biology
  • Pharmacology
  • Cellular biology

Context:

  • Nuclear receptors, particularly PPAR alpha and PPAR gamma, are known for their roles in metabolism.
  • Emerging evidence suggests these receptors also play a crucial role in cellular protection mechanisms.

Purpose:

  • To explore the potential of PPAR agonists in cellular protection.
  • To investigate the molecular pathways involved in PPAR-mediated cellular protection.

Summary:

  • PPAR alpha and PPAR gamma agonists demonstrate protective effects in models of myocardial and cerebral ischemia, and neurodegenerative diseases.
  • Cellular protection mediated by PPARs may involve the modulation of inflammation, oxidative stress, and apoptosis.
  • Specific drugs like fenofibrate, gemfibrozil, ciglitazone, pioglitazone, rosiglitazone, and troglitazone are agonists for PPAR alpha and gamma.

Related Experiment Videos

Impact:

  • Pharmacological modulation of PPARs could represent a novel therapeutic approach for conditions involving cellular damage.
  • Development of highly selective and potent PPAR agonists is a key future direction for enhancing cellular protection strategies.